Story

Aquestive Therapeutics Shares Gain After Positive Anaphylaxis Drug Study Results

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Aquestive Therapeutics Shares Gain After Positive Anaphylaxis Drug Study Results
Text size
Background

Shares of Aquestive Therapeutics (NASDAQ: AQST) surged in pre-market trading after the company reported positive topline results from two pivotal studies for its lead drug candidate, Anaphylm. The drug is a non-invasive, sublingual film designed to treat severe allergic reactions, including anaphylaxis.

Addressing FDA Concerns

The company announced favorable data from a human factors validation study and a self-administration pharmacokinetic study. According to Aquestive, these results directly address concerns raised by the U.S. Food and Drug Administration (FDA) in a Complete Response Letter (CRL) issued in January 2026.

The positive data is a significant milestone, as it removes a key regulatory overhang for the company. Aquestive confirmed that its New Drug Application (NDA) resubmission for Anaphylm remains on track for the third quarter of 2026.

Sample IUX Markets – In-articleAd

Market Impact and Outlook

Following the announcement, Aquestive's stock jumped 9.4% in pre-open trading. The move was driven by the reduced regulatory risk, as investors had been monitoring whether the company could complete the required studies on schedule.

If approved, Anaphylm has the potential to be the first non-invasive epinephrine product for anaphylaxis available in the market, a position that could hold significant commercial value. The muted trading in the broader U.S. equity markets highlighted that the stock's surge was a direct reaction to the company-specific news.

Read next

More on Stocks
Back to latest news

LATEST